FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1	UNID APPRO	VAL
	OMB Number:	3235-0287
	Estimated average burde	n
	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	INER SA	Reporting Person* NDRA A.  irst) WAY	(Middle)		2. Issuer Name and Ticker or Trading Symbol Pulse Biosciences, Inc. [ PLSE ]  3. Date of Earliest Transaction (Month/Day/Year) 11/18/2019							elationship of Reporting Person(s) to Issuer ck all applicable)  Director 10% Owne  Officer (give title Other (specification))  CFO & EVP Admin. and Finance				ner pecify
(Street) HAYWA (City)		A state)	94545 (Zip)		Line						Line)	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			2. Transa Date (Month/D	Execution Date,		Code (Inst	n Dispose	ties Acquire d Of (D) (Insi	d (A) or r. 3, 4 and 5)	5. Amount Securities Beneficial Owned For Reported	ly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V Amount (A) or (D) Prid					Price	Transaction(s) (Instr. 3 and 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, Transact or Exercise (Month/Day/Year) if any Code (In							ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	e s Illy	Ownership of Form: B Direct (D) O	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)	5)	
Stock Option (right to buy)	\$13.94	11/18/2019		A		103,842		11/18/2020 <sup>(1)</sup>	11/18/2029	Common Stock	103,842	\$0.00	103,84	42	D	
Stock Option (right to buy)	\$13.94	11/18/2019		A	v	103,842		(2)	11/18/2029	Common Stock	103,842	\$0.00	103,84	42	D	

## **Explanation of Responses:**

- 1. The shares subject to the option will vest in equal annual installments over the following four years on the anniversary of the grant date, subject to the Reporting Person's continued service through each vesting
- 2. The shares subject to the option shall vest based upon the achievement of performance objectives, with vesting targets set no less than one-fourth (1/4) vesting per year upon achievement of said objectives established by the Compensation Committee of the Issuer, subject to the Reporting Person's continued service through each vesting date. If performance objectives are not set by the Compensation Committee, the shares subject to the option will vest in equal annual installments over the following four years on the anniversary of the grant date, subject to the Reporting Person's continued service through each vesting date.

## Remarks:

/s/ Darrin R. Uecker, as Attorney-in-Fact

\*\* Signature of Reporting Person

11/19/2019

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.